Adagio Medical, Inc., a leading innovator in catheter ablation technologies for ventricular tachycardia ("VT") and atrial fibrillation ("AF"), today announced CE Mark approval of its ultra-low temperature cryoablation ("ULTC") system for the treatment of monomorphic ventricular tachycardia. The system consists of the upgraded cryoablation console, also capable of supporting atrial ablation procedures using commercially available iCLAS™ catheters, and the vCLAS™ ventricular cryoablation catheter

Related Keywords

United States , California , Laguna Hills , New York , Canada , Germany , Canadian , Olav Bergheim , Julian Chun , Boris Schmidt , Adagio Medical Or Aja Holdco Inc , Adagio Medical Inc , Journal Of American College Cardiology , Sciences Acquisition Corp , Company Do , Exchange Commission , Linkedin , Cardiovascular Center Bethanien , American College , Clinical Electrophysiology , Breaking Clinical Science , Atul Verma , Mcgill University Health , Adagio Medical , European Electrophysiology , In Human Experience , Ultra Low Temperature Cryoablation , Monomorphic Ventricular , Rhythm Case Reports , Aja Holdco , Combined Company , Registration Statement , Press Release , Securities Act , Additional Information Regarding , Transaction Will Be Filed With , Acquisition Corp , Ventricular Tachycardia , Ombined Company , Dagio Medical , Edical , Nc , Onomorphic Vt ,